MOLECULAR CANCER THERAPEUTICS

Scope & Guideline

Exploring the molecular mechanisms behind cancer therapies.

Introduction

Welcome to the MOLECULAR CANCER THERAPEUTICS information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of MOLECULAR CANCER THERAPEUTICS, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN1535-7163
PublisherAMER ASSOC CANCER RESEARCH
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 2001 to 2024
AbbreviationMOL CANCER THER / Mol. Cancer Ther.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404

Aims and Scopes

The journal "Molecular Cancer Therapeutics" focuses on advancing the understanding and treatment of cancer through innovative therapeutic strategies. It encompasses a wide array of research dedicated to novel agents, combination therapies, and the mechanisms underlying cancer drug resistance.
  1. Novel Therapeutic Agents:
    The journal features research on newly developed therapeutic agents, including small molecules, antibodies, and antibody-drug conjugates, aimed at targeting specific cancer types and overcoming resistance mechanisms.
  2. Combination Therapies:
    A significant focus is on combination therapies, which explore the synergistic effects of different treatment modalities, such as chemotherapy, immunotherapy, and targeted therapies, to enhance efficacy and reduce resistance.
  3. Mechanisms of Drug Resistance:
    Research delves into the molecular mechanisms that contribute to drug resistance in cancer, providing insights that can guide the development of new therapeutic strategies and improve treatment outcomes.
  4. Biomarker Identification and Validation:
    The identification and validation of biomarkers that predict response to therapies are crucial aspects of the journal, enhancing personalized medicine approaches in oncology.
  5. Preclinical and Clinical Studies:
    The journal publishes findings from both preclinical models and clinical trials, bridging the gap between laboratory research and patient care, thus facilitating the translation of scientific discoveries into therapeutic applications.
  6. Tumor Microenvironment Interactions:
    Research on the interactions between tumors and their microenvironment is emphasized, particularly how these interactions influence treatment response and resistance.
The journal has seen the emergence of several trends that indicate the future direction of cancer research and therapeutics. This section highlights the most significant emerging themes based on recent publications.
  1. Targeted Therapy Innovations:
    There is a significant trend towards the development of highly selective targeted therapies, including PROTACs and small-molecule inhibitors that address specific mutations and pathways in cancer, thereby enhancing treatment precision.
  2. Immunotherapy and Immune Modulation:
    The exploration of immunotherapy continues to gain momentum, with a focus on innovative approaches that enhance the immune response against tumors, including immune checkpoint inhibitors and T-cell engagers.
  3. Biomarker-Driven Treatment Approaches:
    Emerging research emphasizes the importance of biomarker-driven approaches to personalize cancer treatment, allowing for tailored therapies based on individual patient profiles and tumor characteristics.
  4. Nanotechnology in Cancer Therapy:
    The use of nanotechnology for drug delivery systems is on the rise, facilitating targeted and effective delivery of therapeutics to tumor sites while minimizing systemic toxicity.
  5. Exploration of Tumor Microenvironment Dynamics:
    Research increasingly focuses on understanding the tumor microenvironment's role in cancer progression and treatment response, leading to innovative strategies that target both tumor cells and their surrounding stroma.
  6. Combination of Targeted Therapies with Immunotherapy:
    There is a growing interest in the synergistic potential of combining targeted therapies with immunotherapies, which aims to enhance overall treatment efficacy and address resistance mechanisms.

Declining or Waning

As the journal evolves, certain themes may show a decrease in prominence. This section identifies areas that have gradually waned in focus, reflecting shifts in research priorities and advancements in cancer therapeutics.
  1. Traditional Chemotherapy Approaches:
    While traditional chemotherapy remains a cornerstone in cancer treatment, research focusing solely on these approaches is declining as the field shifts towards targeted therapies and immunotherapies that offer more personalized treatment options.
  2. Single-Agent Studies:
    There is a noticeable decrease in studies investigating single-agent therapies, as the trend moves towards exploring combination therapies that leverage synergistic effects for improved outcomes.
  3. Basic Science Without Therapeutic Application:
    Research that focuses primarily on basic cancer biology without direct therapeutic implications or translational relevance is becoming less prevalent, as emphasis grows on studies that can lead to practical treatments.

Similar Journals

ONCOGENE

Illuminating the Pathways of Molecular Oncology
Publisher: SPRINGERNATUREISSN: 0950-9232Frequency: 50 issues/year

ONCOGENE is a premier peer-reviewed journal published by SpringerNature, serving as a crucial platform for innovative research within the fields of Cancer Research, Genetics, and Molecular Biology. With an impressive Impact Factor and a distinguished Q1 ranking across major categories, ONCOGENE publishes cutting-edge studies aimed at unraveling the complexities of cancer biology and genetic mechanisms. The journal has been a vital resource for the academic community since its inception in 1987, and it continues to foster rigorous scientific discussions and collaborations. Researchers, professionals, and students can access a wealth of critical insights and advances in cancer genomics and therapeutic approaches, cementing ONCOGENE’s role as a leading voice in the landscape of biomedical research. For comprehensive academic research, ONCOGENE remains an indispensable source of knowledge with contributions that significantly impact the evolution of cancer research and treatment strategies.

ANTI-CANCER DRUGS

Pioneering Discoveries in Oncology Pharmacology
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0959-4973Frequency: 10 issues/year

ANTI-CANCER DRUGS is a leading journal in the domain of cancer research and pharmacology, published by Lippincott Williams & Wilkins. With its inception dating back to 1990 and ongoing publication through 2024, this journal serves as a vital resource for researchers, clinicians, and students interested in the latest advancements and discoveries in cancer therapeutics. Although classified in the Q3 quartile across relevant categories such as Cancer Research and Oncology, its growing impact is evidenced by its competitive Scopus rankings, positioned within the 30th to 52nd percentiles across various disciplines. The journal remains committed to promoting innovative research that can translate into effective anti-cancer strategies, providing valuable insights into drug development and applications. While it does not currently offer open access, the journal continues to attract a sophisticated readership, making it an essential platform for disseminating significant findings in the ever-evolving field of oncology.

Molecular and Clinical Oncology

Uncovering the molecular secrets of oncology.
Publisher: SPANDIDOS PUBL LTDISSN: 2049-9450Frequency: 12 issues/year

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

CANCER CHEMOTHERAPY AND PHARMACOLOGY

Elevating cancer research with expert reviews and methodologies.
Publisher: SPRINGERISSN: 0344-5704Frequency: 12 issues/year

Cancer Chemotherapy and Pharmacology, published by Springer, is a leading peer-reviewed journal that plays a crucial role in the field of cancer research and drug therapy. With an ISSN of 0344-5704 and an E-ISSN of 1432-0843, this journal has been a cornerstone of oncology and pharmacology research since its inception in 1978, with continued relevance through to 2024. The journal holds a commendable Q2 ranking in categories such as Cancer Research, Oncology, and Pharmacology (medical), while achieving an elite Q1 status in Toxicology, reflecting its high-impact contributions to the scientific community. Researchers and professionals benefit from access to cutting-edge studies, insightful reviews, and innovative methodologies, making it a vital resource for anyone working at the intersection of pharmacology and oncology. Although not an open-access journal, Cancer Chemotherapy and Pharmacology remains highly accessible through institutional subscriptions, ensuring it reaches a broad audience dedicated to advancing cancer treatment and patient care.

Oncologie

Exploring innovative solutions in oncology.
Publisher: WALTER DE GRUYTER GMBHISSN: 1292-3818Frequency: 6 issues/year

Oncologie is a distinguished academic journal published by WALTER DE GRUYTER GMBH, focusing on the dynamic and vital field of oncology. Established in 1999 and continuously published until 2024, this journal provides a platform for high-quality research and advancements in cancer treatment, prevention, and diagnosis. With an ISSN of 1292-3818 and an E-ISSN of 1765-2839, it is indexed in various databases, contributing to its growing visibility. Although categorized in the Q3 quartile for oncology research as of 2023, Oncologie offers essential insights and fosters scholarly dialogue among researchers, professionals, and students interested in oncology. Its unique contributions aim to bridge the gap between theoretical frameworks and clinical applications, making it a valuable resource for those seeking to advance their knowledge and expertise in cancer research.

Recent Patents on Anti-Cancer Drug Discovery

Navigating the Landscape of Anti-Cancer Innovations
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1574-8928Frequency: 4 issues/year

Recent Patents on Anti-Cancer Drug Discovery, published by Bentham Science Publishers Ltd, is an esteemed peer-reviewed journal specializing in the innovative intersection of pharmaceutical science and oncology. With an ISSN of 1574-8928 and an E-ISSN of 2212-3970, this journal aims to provide a comprehensive platform for the dissemination of recent developments in anti-cancer drug discovery, addressing critical issues and breakthroughs that influence cancer research and treatment. The journal spans from 2006 to 2024 and is indexed in several prestigious databases, showcasing its relevance with a Q3 ranking in key categories such as Cancer Research and Drug Discovery as of 2023. Its status of being open access reflects a commitment to making valuable scientific findings widely available, promoting collaboration and advancement in the field. With a dedicated focus on advancing knowledge in cancer therapeutics, the journal serves as a vital resource for researchers, healthcare professionals, and students aiming to contribute to the fight against cancer.

CANCER GENE THERAPY

Exploring Breakthroughs in Cancer Gene Innovations
Publisher: SPRINGERNATUREISSN: 0929-1903Frequency: 12 issues/year

Cancer Gene Therapy, published by SpringerNature, stands at the forefront of research in the fields of cancer research, molecular biology, and molecular medicine. With a robust impact factor reflecting its significant influence—ranking in the Q2 category for cancer research and Q1 for both molecular biology and molecular medicine—it serves as an essential resource for scholars and practitioners alike. Since its inception in 1994, the journal has dedicated itself to advancing the understanding and therapeutic application of genetic innovations in oncology. Notably, it holds distinguished Scopus ranks, placing it among the top tier journals in its categories, underscoring its importance to the scientific community. While open access options are not available, the compelling research published here offers invaluable insights into the latest advancements and strategies in cancer therapy. Engaging with *Cancer Gene Therapy* not only keeps professionals informed but also inspires future innovations in the quest for effective cancer treatments.

Trends in Cancer

Uncovering Breakthroughs in Cancer Biology and Therapy
Publisher: CELL PRESSISSN: 2405-8025Frequency: 12 issues/year

Trends in Cancer is a leading journal published by CELL PRESS, dedicated to advancing the field of cancer research and oncology. Since its inception in 2015, the journal has rapidly gained a reputation for excellence, securing both Q1 rankings in Cancer Research and Oncology categories for 2023 and boasting impressive Scopus ranks—#13 out of 404 in Medicine Oncology and #9 out of 230 in Biochemistry, Genetics and Molecular Biology, thus placing it in the top 4% of its field. The journal aims to publish high-quality, innovative research that offers new insights into cancer biology and treatment strategies. With a commitment to scholarly rigor and a broad scope that encompasses molecular mechanisms to therapeutic approaches, Trends in Cancer serves as an essential resource for researchers, professionals, and students eager to stay informed about the latest developments in cancer science. Although it is not an open-access journal, its contributions are pivotal in shaping the future of cancer research.

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Advancing the Frontiers of Cancer Research
Publisher: ELSEVIERISSN: 0304-419XFrequency: 4 issues/year

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, published by Elsevier, has established itself as a leading journal in the domains of cancer research, genetics, and oncology, holding a prestigious position in the Q1 quartile rankings in these fields as of 2023. With an ISSN of 0304-419X and an E-ISSN of 1879-2561, this journal aims to disseminate high-quality, impactful reviews that synthesize the latest advancements and findings in cancer biology, treatment modalities, and genomic studies. Its robust indexing and remarkable Scopus rankings—placing it in the 95th to 91st percentiles across various categories—underline its significance for researchers, clinicians, and students passionate about oncology. Operating from its Netherlands headquarters, BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER is dedicated to fostering a comprehensive understanding of the complex biological mechanisms underlying cancer, promoting innovative therapeutic strategies, and guiding future research directions.

MOLECULAR CANCER RESEARCH

Transforming Research into Revolutionary Treatments
Publisher: AMER ASSOC CANCER RESEARCHISSN: 1541-7786Frequency: 12 issues/year

MOLECULAR CANCER RESEARCH, published by the American Association for Cancer Research, stands as a pivotal journal in the fields of cancer research, molecular biology, and oncology. With an impressive impact factor and recognized as a Q1 journal in its respective categories for 2023, it serves as an essential resource for researchers, professionals, and students aimed at advancing our understanding of cancer mechanisms and therapies. The journal, identified by the ISSN 1541-7786 and E-ISSN 1557-3125, provides a platform for cutting-edge research and clinical applications, emphasizing innovation and collaboration within the scientific community. With its focus on high-quality, peer-reviewed articles, MOLECULAR CANCER RESEARCH is vital for anyone looking to stay abreast of significant advancements in cancer biology and treatment strategies. For more details and to access the journal's content, please visit the publisher's link.